Tumour necrosis factor-alpha-induced glucose-stimulated insulin secretion inhibition in INS-1 cells is ascribed to a reduction of the glucose-stimulated Ca2+ influx

J Endocrinol. 2008 Sep;198(3):549-60. doi: 10.1677/JOE-08-0131. Epub 2008 Jul 1.

Abstract

The present study was undertaken to determine how tumour necrosis factor-alpha (TNF-alpha) elicits the inhibition of glucose-stimulated insulin secretion (GSIS) in rat insulinoma cells (INS)-1 beta-cells. TNF-alpha pretreatment did not change the expression levels of insulin, PDX-1, glucose transporter 2, glucokinase, K(ATP) channels, Ca(2)(+) channels, and exocytotic molecules and, furthermore, did not reduce the glucose-stimulated ATP level. On the other hand, TNF-alpha reduced the glucose-stimulated influx of Ca(2)(+). The TNF-alpha treatment was thought to activate c-Jun N-terminal kinase (JNK), p38 mitogen-activated protein kinase (MAPK), and NF-kappaB inflammatory signals, since TNF-alpha increased phospho-JNK and phospho-p38 and reduced I kappaB levels. Inhibitors of these signaling pathways prevented the TNF-alpha-induced reduction of the Ca(2)(+) influx and GSIS. Overexpression of MEKK3, a possible mediator from the TNF-alpha receptor to the JNK/p38 and NK-kappaB signaling cascade, increased the levels of phospho-JNK, phospho-p38, and NF-kappaB, and reduced the glucose-stimulated Ca(2)(+) influx and GSIS. The reduction of the Ca(2)(+) influx and GSIS in MEKK3-overexpressing INS-1 cells was also prevented by inhibitors of JNK, p38, and NF-kappaB. These data demonstrate that TNF-alpha inhibits GSIS by reducing the glucose-stimulated Ca(2)(+) influx, possibly through the activation of JNK and p38 MAPK and NF-kappaB inflammatory signals. Thus, our findings suggest that the activation of stress and inflammatory signals can contribute to the inhibition of GSIS in the development of diabetes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP-Binding Cassette Transporters / genetics
  • Adenosine Triphosphate / metabolism
  • Animals
  • Biological Transport / drug effects*
  • Calcium / metabolism*
  • Calcium Channels / genetics
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Gene Expression / drug effects
  • Glucokinase / genetics
  • Glucose / pharmacology*
  • Glucose Transporter Type 2 / genetics
  • Homeodomain Proteins / genetics
  • Immunoblotting
  • Insulin / metabolism*
  • Insulin Secretion
  • Insulinoma
  • JNK Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • JNK Mitogen-Activated Protein Kinases / metabolism
  • MAP Kinase Kinase Kinase 3 / genetics
  • MAP Kinase Kinase Kinase 3 / physiology
  • NF-kappa B / antagonists & inhibitors
  • NF-kappa B / metabolism
  • Nitric Oxide Synthase Type II / genetics
  • Potassium Channels, Inwardly Rectifying / genetics
  • Radioimmunoassay
  • Rats
  • Receptors, Drug / genetics
  • Reverse Transcriptase Polymerase Chain Reaction
  • Sulfonylurea Receptors
  • Trans-Activators / genetics
  • Tumor Necrosis Factor-alpha / pharmacology*
  • p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • ATP-Binding Cassette Transporters
  • Calcium Channels
  • Glucose Transporter Type 2
  • Homeodomain Proteins
  • Insulin
  • Kir6.2 channel
  • NF-kappa B
  • Potassium Channels, Inwardly Rectifying
  • Receptors, Drug
  • Slc2a2 protein, rat
  • Sulfonylurea Receptors
  • Trans-Activators
  • Tumor Necrosis Factor-alpha
  • pancreatic and duodenal homeobox 1 protein
  • Adenosine Triphosphate
  • Nitric Oxide Synthase Type II
  • Glucokinase
  • JNK Mitogen-Activated Protein Kinases
  • p38 Mitogen-Activated Protein Kinases
  • MAP Kinase Kinase Kinase 3
  • Glucose
  • Calcium